Intervention
Dalpiciclib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 26 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerNCT07610720 · 2026-06-01
RECRUITINGA Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.NCT07207070 · 2025-11-12
RECRUITINGDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerNCT07492394 · 2025-09-12
RECRUITINGEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast CancerNCT05578053 · 2024-09-13
RECRUITINGEfficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerNCT06341894 · 2023-11-17
RECRUITINGDalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）NCT06107673 · 2023-09-30
RECRUITINGPARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerNCT05759546 · 2023-02-01
RECRUITINGSNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30
RECRUITINGPyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerNCT05638594 · 2022-12-20
RECRUITINGFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITINGTolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNCT07706933 · 2026-08-01
NOT_YET_RECRUITINGBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesNCT07539753 · 2026-06-01
NOT_YET_RECRUITINGExploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorNCT06556862 · 2025-10-01
NOT_YET_RECRUITINGMaintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNCT07179939 · 2025-09-10
NOT_YET_RECRUITINGDalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNCT07101159 · 2025-09-01
NOT_YET_RECRUITINGMultigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast CancerNCT06650748 · 2025-05-01
ENROLLING_BY_INVITATIONAlbumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABCNCT06711094 · 2025-01-01
NOT_YET_RECRUITINGAn Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast CancerNCT06613373 · 2024-10-15
NOT_YET_RECRUITINGPARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerNCT06612814 · 2024-09-01
ACTIVE_NOT_RECRUITINGDalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNCT05806671 · 2023-05-01
UNKNOWNApatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerNCT05759572 · 2023-03-01
ACTIVE_NOT_RECRUITINGExploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)NCT05577923 · 2022-11-01
UNKNOWNExploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb StudyNCT05586841 · 2022-10-01
COMPLETEDDalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerNCT05512780 · 2022-09-10
UNKNOWNDalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerNCT05574881 · 2022-09-01
UNKNOWNPyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerNCT03772353 · 2019-05-12
UNKNOWNCommon conditions
Breast Cancer14Breast Cancer Metastatic3HR+/HER2- Advanced Breast Cancer3Breast Neoplasm2Early Breast Cancer2Early-stage Breast Cancer2HER2-negative Breast Cancer2HER2-positive Breast Cancer2Hormone Receptor Positive Tumor2Adjuvant Therapy1Advanced Breast Cancer1Advanced/Metastatic Breast Cancer1Brain Metastases1Breast Tumors1HER2-Positive Metastatic Breast Cancer1Hormone Receptor Negative Tumor1Hormone Receptor Positive / HER2-negative Breast Cancer1HR+/HER2- Breast Cancer1Locally Advanced Breast Cancer1Metastatic Breast Cancer1Solid Tumor1Triple-Negative Breast Cancer (TNBC)1
Leading sponsors
Fudan University
8
Hebei Medical University Fourth Hospital
4
Beijing 302 Hospital
2
Fujian Cancer Hospital
1
Fujian Medical University
1
Henan Cancer Hospital
1
Jiangsu Famous Medical Technology Co., Ltd.
1
Nanfang Hospital, Southern Medical University
1
Peking University
1
Risen (Suzhou) Pharma Tech Co., Ltd.
1
Shengjing Hospital
1
Sun Yat-sen University
1
The First Affiliated Hospital with Nanjing Medical University
1
Tianjin Medical University Cancer Institute and Hospital
1
Zhimin Shao
1
Trial status mix
RECRUITING10
NOT_YET_RECRUITING7
UNKNOWN5
ACTIVE_NOT_RECRUITING2
COMPLETED1
ENROLLING_BY_INVITATION1
Phase mix
PHASE219
PHASE13
NA2
PHASE32
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.